Viron Launches Identification of the Combinatorial Use of Small Molecules as Drugs to Target ‘Undruggable' Porosome Proteins

Viron Inc., uses a proprietary porosome proteome- & lipidome-based platform technology that addresses the key limitations of conventional screening techniques and allows us to discover previously unknown functional protein and lipid targets involved in cell secretion, and identify small molecules that selectively bind to those targets, including undruggable targets and modulate secretory function in the treatment of diseases such as cancers, diabetes and neurological disorders. At Viron, prior to clinical trials, the potency and efficacy of the combinatorial use of small molecule drug formulations, are first assessed in silico by their binding affinities to the target porosome proteins and or lipids, followed by studies on cell culture, human organoids and animal studies.